Abdul Mullick

Abdul currently serves as President & Chief Executive Officer of Kyowa Kirin International plc (KKI), a subsidiary of Kyowa Kirin Co., Ltd. the Japan-based global specialty pharmaceutical company. During his time at KKI, Abdul successfully led the launch of two new rare disease products across Europe, the GCC and other growth markets. He also led a drive to enhance patient and customer care, resulting in improved profitability, as well as accelerating the digital transformation across the entire value chain.

Prior to KKI, Abdul held senior positions at Vifor Pharma as Head of Global Strategic Marketing, Novartis as Global Head of the Diabetes Franchise and at Sanofi where he held roles at the country, regional and global levels. Most notably, he spent over eight years at Genzyme leading rare and ultra-rare disease businesses in Europe, Asia (including China and Japan) and the United States, as well as heading the rare disease global strategy and marketing function.

Abdul graduated with a PhD in Molecular Biology from Bristol University in the UK.